Abstract
Objectives Recent studies show that Test Positivity Rate (TPR) gain a better correlation than incidence with the number of hospitalized patients in COVID-19 pandemic. Nevertheless, epidemiologist remain sceptical concerning the widespread use of this metric for surveillance, and indicators based on known cases like incidence are still preferred despite the large number of asymptomatic carriers which remain unknown. Our aim is to compare TPR and incidence, to determine which of the two has the best characteristics to predict the trend of hospitalized patients in COVID-19 pandemic.
Methods We perform a retrospective study considering 60 cases, using global and local data from Italy in different waves of the pandemic, in order to detect peaks in TPR time series, and peaks in incidence, finding which of the two has the best ability to anticipate peaks in patients admitted in hospitals.
Results On average the best TPR based approach anticipates incidence of about 4.6 days (95% CI 2.8, 6.4), more precisely the average distance between TPR peaks and hospitalized peaks is 17.6 days (95% CI 15.0, 20.4) with respect to 13.0 days (95% CI 10.4, 15.8) obtained for incidence. Moreover, the average difference between TPR and incidence increases to more than 6 days in the Delta outbreak during Summer 2021, where presumably the percentage of asymptomatic carriers was larger.
Conclusions We conclude that TPR should be used as primary indicator to enable early intervention and for planning hospitals admissions in infectious diseases with asymptomatic carriers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
email: mauro.gaspari{at}unibo.it
Data Availability
All data produced in the present study are available upon reasonable request to the authors
